HeartBeam CEO Departs, Director Resigns Amid Strategic Pivot to Licensing Model

summarizeSummary

HeartBeam announced a major strategic reorganization, including the departure of its CEO and a director, as it shifts its business model to licensing its 3D ECG technology for global adoption and a leaner cost structure.

check_boxKey Events

• CEO Robert Eno Departs

  Robert P. Eno mutually agreed to depart as Chief Executive Officer, Board member, and principal executive officer, effective June 30, 2026, as part of a strategic reorganization. He is expected to transition to a consulting role.

• Interim Leadership Appointed

  Branislav Vajdic, Ph.D., Founder and President, will serve as the principal executive officer, and Rich Ferrari, Executive Chairman, will lead focused implementation teams during the transition.

• Director Mark Strome Resigns

  Mark Strome resigned from the Board of Directors and all committees, effective immediately. This follows his significant stock purchase in the company's April public offering.

• Major Strategic Business Model Shift

  The company is pivoting from direct medical device sales to licensing its 3D ECG signal technology to established partners, aiming for global market reach and a 'meaningfully lower cost structure'.

auto_awesomeAnalysis

This 8-K announces a significant strategic reorganization for HeartBeam, including the departure of CEO Robert Eno and Director Mark Strome. The company is pivoting its business model from direct sales to a licensing strategy for its 3D ECG signal technology, aiming for global adoption and a 'meaningfully lower cost structure.' This major shift, coupled with leadership changes, is critical for a micro-cap company that recently raised capital and continues to face a 'going concern' warning, as it seeks a more capital-efficient path to commercialization and expansion into new areas like heart attack detection.